Johannesburg News Today | 2 Min News | The Daily News Now!
For the first time ever, Merck is letting generic makers start producing its new HIV prevention pill, alimatravir, before final trials wrap up — a bold move that could slash new infections in South Africa by hundreds of thousands. Three of seven licenses went to African firms, including Aspen Pharmacare, accelerating local manufacturing and access across low- and middle-income countries. This next-gen drug, which works differently than current HIV meds, offers a monthly option that may improve adherence. Early data shows safety and rapid absorption, with phase three trials ongoing in 17 countries. The strategy aims to break the global pattern of rich nations getting new drugs first — but activists note some middle-income countries were excluded from distribution plans, and demand must be strong enough to justify massive production. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/d8d6fdf895c068d2
300 episoder
Kommentarer
0Vær den første til at kommentere
Tilmeld dig nu og bliv en del af Johannesburg News Today | 2 Min News | The Daily News Now!-fællesskabet!